Install
News of the Day Anticipated therapies and not-so-anticipated dominate July PBAC agenda GSK brings Melbourne discovered treatment 'home' to Australian patients New government report reveals the emerging impact of generational reform Health department quietly launches major review of blood products supply Budget reveals
- 34articles · 30d
- 10+ hour agolatest article
- Aug 17, 2026earliest in window
- 94%with images
- 133avg words
- Medical 29
- Health & Wellness 25
- Health 23
- Business & Industrial 9
- Economy, Business & Finance 4
- Finance & Business 4
- Science & Technology 4
- Human Interest 1
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Entropy's psychedelic infusion keeps binge eating disorder at bay three months after treatment ends
10+ hour, 29+ min ago (131+ words) PharmaDispatch Entropy's psychedelic infusion keeps binge eating disorder at bay three months after treatment ends Six patients who had lived with binge eating disorder for as long as two decades sat down for two infusions of an experimental psychedelic drug....
GSK therapy becomes first biologic subsidised for Australians with uncontrolled COPD
1+ week, 6+ day ago (161+ words) PharmaDispatch GSK therapy becomes first biologic subsidised for Australians with uncontrolled COPD Lung Foundation Australia chief executive Mark Brooke said, "Living with uncontrolled COPD can be incredibly challenging. Managing breathlessness, infections and repeated flare-ups can be a source of ongoing…...
Alterity secures option underwriting as it prepares for pivotal MSA trial
2+ week, 13+ hour ago (140+ words) PharmaDispatch Alterity secures option underwriting as it prepares for pivotal MSA trial Alterity Therapeutics has secured an underwriting agreement that could provide at least $4.2 million in additional funding as the company prepares to begin its planned Phase 3 clinical trial of…...
Avecho resumes pivotal insomnia trial recruitment after positive interim review
2+ week, 13+ hour ago (134+ words) PharmaDispatch Avecho resumes pivotal insomnia trial recruitment after positive interim review Avecho Biotechnology has restarted recruitment for the final stage of its pivotal Phase 3 trial of a cannabidiol capsule designed to treat insomnia, after an independent review found the study…...
Entropy takes TRP-8803 to the US in head-to-head depression trial - BioPharmaDispatch
2+ week, 5+ day ago (143+ words) Entropy takes TRP-8803 to the US in head-to-head depression trial PharmaDispatch Entropy takes TRP-8803 to the US in head-to-head depression trial Entropy Neurodynamics has signed an agreement with the University of California, San Francisco, to develop a US Phase 2 trial…...
Avecho moves to deepen global partnering push as CBD insomnia program advances
3+ week, 13+ hour ago (102+ words) PharmaDispatch Avecho moves to deepen global partnering push as CBD insomnia program advances Avecho chief executive Dr Paul Gavin said the timing reflected the program's growing commercial relevance as it approaches a critical clinical and regulatory stage. … July recommendations across…...
Opportunity #1 - biosimilar policy failure has become impossible to ignore
3+ week, 6+ day ago (136+ words) PharmaDispatch Opportunity #1 - biosimilar policy failure has become impossible to ignore If the promise of biosimilars is only savings for the government, rather than savings and wider access, what is the point from a patient perspective? The one-dimensional focus on savings…...